Literature DB >> 7053533

Non-Hodgkin lymphoma of the testis.

B S Tepperman, M K Gospodarowicz, R S Bush, T C Brown.   

Abstract

Sixteen patients (median age 67 yrs.) with non-Hodgkin lymphoma of the testis were studied. Twelve of these patients had disease that was classified as local (Stages IE and IIE). Eight patients had diffuse histiocytic lymphoma, 6 had diffuse poorly differentiated lymphocytic lymphoma, 1 had both lymphoma and seminoma, and 1 had nodular poorly differentiated lymphocytic lymphoma. The overall median survival was 9.5 months. Para-aortic nodal involvement was the factor that had the strongest prognostic influence with the management methods used. Median survival without para-aortic nodal involvement was 57+ months, but with such involvement it was 6 months (p = 0.002). There is a high probability of generalized disease if lymphoma can be detected in the para-aortic nodes. For patients with Stages IE and IIE disease, radical radiation therapy is the preferred treatment. For those with disseminated disease, chemotherapy, with irradiation reserved for symptomatic and bulky localized deposits, is the recommended method of management.

Entities:  

Mesh:

Year:  1982        PMID: 7053533     DOI: 10.1148/radiology.142.1.7053533

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Primary testicular non-Hodgkin's lymphoma associated with hemophagocytic syndrome: Case report and review of the literature.

Authors:  Weigang Ren; Zhaohui Zhong; Xiaokun Zhao; Junjie Yang; Lei Zhang; Ran Xu; Songchao Li; Xuan Zhu; Chen Lu; Joseph L Chin
Journal:  Oncol Lett       Date:  2012-04-30       Impact factor: 2.967

2.  Primary testicular lymphoma with subcutaneous masses as the sole manifestation of the first relapse and central nervous system lymphoma as the second relapse: A case report and literature review.

Authors:  Zunguo DU; Yin Wang; Ping Zhu; Haiyan Leng; Feng Tang; Xiaoping Xu; Zi Chen
Journal:  Oncol Lett       Date:  2014-04-09       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.